March 13, 2014
1 min read
Save
This article is more than 5 years old. Information may no longer be current.
ThromboGenics awarded €3 million grant for research into DME treatment
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
ThromboGenics has been awarded a €3 million grant from the Flemish agency for Innovation by Science and Technology to be used for research into potential new biotherapeutics for the treatment of diabetic macular edema, according to a press release.
The therapeutics will be aimed at reducing vascular leakage and inflammation.
ThromboGenics will use the grant funding to attempt to identify preclinical candidates that meet a target product profile based around in vitro potency, in vivo efficacy and drug-like properties, the release said.
The candidates will use ThromboGenics’ AMP-Rx protein design technology, which was licensed from Eleven Biotherapeutics in May 2013, the release said.